Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 359

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 359
---
, stool, blood, and tissue), as well as qualitative sources (clinical and lifestyle), through our commercialization efforts to further improve our products. We are currently developing AI tools to enhance the precision, actionability, and efficiency of our services. Our prospective AI -poweredcapabilities aim at processing diverse biological and qualitative data, such as genomic, clinical and lifestyle information. We further seek to utilize proprietary machine learning algorithms and third -partyLarge Language Models (“LLMs”) that are fine -tunedwith our own data to analyze genomic data, and process and integrate information to present even more precise and actionable results, comprehensive reports, and to automate operational tasks which include the reduction of result turnaround times. Looking ahead, we will implement a phased plan to expand our AI capabilities over the next two to three years. This expansion aims to integrate deeper health insights into our current product offerings, provide 176 more tailored counseling, and improve analytics for prevention and personalized care. We anticipate broader applications, such as advanced research, drug discovery, and clinical trials, to be developed within five years. These initiatives will be supported by investments in proprietary data integration and bioinformatics tools, along with collaboration with internal and external experts, to enhance the scalability and sophistication of our future AI systems. • Making genetic information more accessible and equitable: as sequencing and technology costs decrease over time, we are determined to keep healthcare within reach and committed to making genetic services more accessible and affordable. • Focusing on actionable results: we are dedicated to delivering personalized, clinically actionable insights that empower individuals to make informed health decisions. We aim to proactively address potential or unidentified health issues, providing individuals with the knowledge they need to take control of their health and well -being. • Ensuring privacy, security and reliability: we are committed to ensuring that our users’ genetic, clinical and lifestyle data and information is treated with the highest standards of confidentiality and integrity. To protect sensitive customer data, we employ comprehensive safeguards, including encryption, access controls, data anonymization, and compliance with relevant data protection regulations, prioritizing security and privacy at each stage of AI development. Currently, all AI developments are conducted in -house, ensuring strict oversight. We believe that timely and precise genomic insights play a critical role in revolutionizing individual health management. In today’s landscape, reliable genetic data remains elusive for many, leaving them vulnerable to undetected disease -pronegenetic variants. According to the American Association for the Advancement of Science, one in five healthy adults may carry such variants, without knowing it. If